{"transactions":[{"id":672265,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-08-31T14:29:08.000Z","date":"2026-08-28","kind":"purchase","planned":false,"acquired":true,"shares":7984,"price":1.089,"value":8694.576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein."}],"balance_after":2070000,"source":{"system":"sec-edgar","filing":"0001437749-26-029257","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926029257/rdgdoc.xml","form_type":"4/A","original_submission_date":"2026-08-29"}},{"id":672264,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-08-31T14:29:08.000Z","date":"2026-08-27","kind":"purchase","planned":false,"acquired":true,"shares":789,"price":1.07,"value":844.23,"ownership":{"direct":true},"balance_after":2062016,"source":{"system":"sec-edgar","filing":"0001437749-26-029257","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926029257/rdgdoc.xml","form_type":"4/A","original_submission_date":"2026-08-29"}},{"id":673283,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-08-29T01:46:35.000Z","date":"2026-08-28","kind":"grant","planned":false,"acquired":true,"shares":7984,"price":1.089,"value":8694.576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.08 to $1.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein."}],"balance_after":2070000,"source":{"system":"sec-edgar","filing":"0001437749-26-029236","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926029236/rdgdoc.xml","form_type":"4"}},{"id":673282,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-08-29T01:46:35.000Z","date":"2026-08-27","kind":"grant","planned":false,"acquired":true,"shares":789,"price":1.07,"value":844.23,"ownership":{"direct":true},"balance_after":2062016,"source":{"system":"sec-edgar","filing":"0001437749-26-029236","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926029236/rdgdoc.xml","form_type":"4"}},{"id":719169,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to purchase common stock","published_at":"2026-07-03T01:02:37.000Z","date":"2026-06-29","kind":"grant","planned":false,"acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"One third of the options are exercisable as of June 30, 2027 and the balance vest quarterly over the subsequent two years."}],"balance_after":125000,"derivative":{"exercise_price":1.01,"expiration_date":"2036-06-29","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001437749-26-022665","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926022665/rdgdoc.xml","form_type":"4"}},{"id":719168,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to purchase common stock","published_at":"2026-07-03T01:02:37.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":false,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"62,500 options exercisable on 07/01/2016, 50,000 options exercisable on 03/31/2017, and 50,000 options exercisable on 12/31/2017."}],"balance_after":0,"derivative":{"exercise_price":1,"exercise_date":"2017-12-31","expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001437749-26-022665","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926022665/rdgdoc.xml","form_type":"4"}},{"id":719167,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-07-03T01:02:37.000Z","date":"2026-06-30","kind":"tax_withholding","planned":false,"acquired":false,"shares":160892,"price":1.01,"value":162500.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a net exercise of outstanding stock options. The reporting person received 1,608 shares of common stock on the net exercise of option to purchase 162,500 shares of common stock. The issuer withheld 160,892 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.01."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4."}],"balance_after":2061227,"source":{"system":"sec-edgar","filing":"0001437749-26-022665","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926022665/rdgdoc.xml","form_type":"4"}},{"id":719166,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-07-03T01:02:37.000Z","date":"2026-06-30","kind":"exercise","planned":false,"acquired":true,"shares":162500,"price":1,"value":162500.0,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects an adjustment of 25,381 shares since the Reporting Person's most recent Form 4 filed June 5, 2026 to correct the amount of securities beneficially owned as a result of the transaction reported in that Form 4."}],"balance_after":2222119,"source":{"system":"sec-edgar","filing":"0001437749-26-022665","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926022665/rdgdoc.xml","form_type":"4"}},{"id":748624,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-06-05T22:34:26.000Z","date":"2026-06-05","kind":"grant","planned":false,"acquired":true,"shares":13245,"price":1.0952,"value":14505.924,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $1.042 to $1.15, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate transaction with the range set forth herein."}],"balance_after":2085000,"source":{"system":"sec-edgar","filing":"0001437749-26-019768","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926019768/rdgdoc.xml","form_type":"4"}},{"id":953102,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to purchase common stock","published_at":"2026-01-06T00:25:34.000Z","date":"2018-12-31","kind":"exercise","planned":false,"acquired":false,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2018-12-31","expiration_date":"2026-01-01","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001437749-26-000431","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926000431/rdgdoc.xml","form_type":"4"}},{"id":953101,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-01-06T00:25:34.000Z","date":"2026-01-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":25381,"price":1.97,"value":50000.57,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a net exercise of outstanding stock options. The reporting person received 99,619 shares of common stock on the net exercise of option to purchase 125,000 shares of common stock. The issuer withheld 25,381 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.97."}],"balance_after":2046374,"source":{"system":"sec-edgar","filing":"0001437749-26-000431","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926000431/rdgdoc.xml","form_type":"4"}},{"id":953100,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2026-01-06T00:25:34.000Z","date":"2026-01-01","kind":"exercise","planned":false,"acquired":true,"shares":125000,"price":0.4,"value":50000.0,"ownership":{"direct":true},"balance_after":2071755,"source":{"system":"sec-edgar","filing":"0001437749-26-000431","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774926000431/rdgdoc.xml","form_type":"4"}},{"id":982418,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2025-12-03T23:13:16.000Z","date":"2025-11-28","kind":"sale","planned":false,"acquired":false,"shares":200000,"price":1.5,"value":300000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transaction reported herein was made in a private transaction to facilitate a personal real estate transaction whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":1946755,"source":{"system":"sec-edgar","filing":"0001437749-25-036821","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925036821/rdgdoc.xml","form_type":"4"}},{"id":1076654,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to purchase common stock","published_at":"2025-08-04T13:09:44.000Z","date":"2018-08-09","kind":"exercise","planned":false,"acquired":false,"shares":192710,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2018-08-09","expiration_date":"2025-08-08","underlying":"Common Stock","underlying_shares":192710},"source":{"system":"sec-edgar","filing":"0001437749-25-024497","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024497/rdgdoc.xml","form_type":"4"}},{"id":1076653,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2025-08-04T13:09:44.000Z","date":"2025-08-01","kind":"tax_withholding","planned":false,"acquired":false,"shares":21313,"price":1.74,"value":37084.62,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Represents a net exercise of outstanding stock options. The reporting person received 71,397 shares of common stock on the net exercise of option to purchase 92,710 shares of common stock. The issuer withheld 21,313 shares of common stock underlying the option for payment of the exercise price using the closing price of $1.74."}],"balance_after":2146755,"source":{"system":"sec-edgar","filing":"0001437749-25-024497","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024497/rdgdoc.xml","form_type":"4"}},{"id":1076652,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2025-08-04T13:09:44.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":92710,"price":0.4,"value":37084.0,"ownership":{"direct":true},"balance_after":2168068,"source":{"system":"sec-edgar","filing":"0001437749-25-024497","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024497/rdgdoc.xml","form_type":"4"}},{"id":1076651,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2025-08-04T13:09:44.000Z","date":"2025-08-01","kind":"exercise","planned":false,"acquired":true,"shares":100000,"price":0.4,"value":40000.0,"ownership":{"direct":true},"balance_after":2075358,"source":{"system":"sec-edgar","filing":"0001437749-25-024497","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774925024497/rdgdoc.xml","form_type":"4"}},{"id":2118695,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":5000,"price":1.5,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":1975358,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118694,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":7000,"price":1.5,"value":10500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":1980358,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118693,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":10000,"price":1.5,"value":15000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":1987358,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118692,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":13500,"price":1.5,"value":20250.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":1997358,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118691,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":20000,"price":1.5,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":2010858,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118690,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":20000,"price":1.5,"value":30000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":2030858,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118689,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":27000,"price":1.5,"value":40500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":2050858,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118688,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":30000,"price":1.5,"value":45000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":2077858,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2118687,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-11-14T23:43:28.000Z","date":"2022-11-09","kind":"sale","acquired":false,"shares":30000,"price":1.5,"value":45000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported herein were made in private transactions to various persons whereby the shares of common stock acquired constitute \"restricted\" securities within the meaning of the Securities Act of 1933, as amended."}],"balance_after":2107858,"source":{"system":"sec-edgar","filing":"0001437749-22-027386","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922027386/rdgdoc.xml","form_type":"4"}},{"id":2286888,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-05-02T16:23:53.000Z","date":"2022-04-29","kind":"grant","acquired":true,"shares":10532,"price":1,"value":10532.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"}],"balance_after":2137858,"source":{"system":"sec-edgar","filing":"0001437749-22-010382","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922010382/rdgdoc.xml","form_type":"4"}},{"id":2290517,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to Purchase Common Stock","published_at":"2022-04-27T01:29:41.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125000,"derivative":{"exercise_price":0.75,"exercise_date":"2022-03-04","expiration_date":"2032-03-04","underlying":"Common Stock","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001437749-22-009786","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009786/rdgdoc.xml","form_type":"4"}},{"id":2290516,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Option to Purchase Common Stock","published_at":"2022-04-27T01:29:41.000Z","date":"2022-03-04","kind":"grant","acquired":true,"shares":66672,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"Granted in settlement of compensation liability for period January 1, 2019 through April 30, 2019"}],"balance_after":66672,"derivative":{"exercise_price":0.5,"exercise_date":"2022-03-04","expiration_date":"2032-03-04","underlying":"Common Stock","underlying_shares":66672},"source":{"system":"sec-edgar","filing":"0001437749-22-009786","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009786/rdgdoc.xml","form_type":"4"}},{"id":2290509,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-30","kind":"exercise","acquired":false,"shares":1137635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.2,"exercise_date":"2021-12-01","expiration_date":"2022-01-31","underlying":"Common Stock","underlying_shares":1137635},"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290508,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-06","kind":"other","acquired":false,"shares":160000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F5","text":"Transferred to third party for no consideration"}],"balance_after":1137635,"derivative":{"exercise_price":0.4,"exercise_date":"2021-12-01","expiration_date":"2022-01-31","underlying":"Common Stock","underlying_shares":160000},"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290507,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-01","kind":"disposition_to_issuer","acquired":false,"shares":397635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F4","text":"Cancelled in accordance with Warrant Modification Agreement  dated as of 12/01/21"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2020-10-05","expiration_date":"2025-10-05","underlying":"Common Stock","underlying_shares":397635},"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290506,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-01","kind":"disposition_to_issuer","acquired":false,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F4","text":"Cancelled in accordance with Warrant Modification Agreement  dated as of 12/01/21"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price."}],"balance_after":0,"derivative":{"exercise_price":0.4,"exercise_date":"2020-10-05","expiration_date":"2025-10-05","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290505,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-01","kind":"grant","acquired":true,"shares":1297635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired in accordance with Warrant Modification Agreement  dated as of 12/01/21"},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The reported transactions relate to an amendment of the exercise price of outstanding warrants contingent upon the Reporting Person exercising the warrants. As a result, the outstanding warrants were deemed cancelled and modified warrants were issued for the same number of shares of Common Stock, but with a reduced exercise price."}],"balance_after":1297635,"derivative":{"exercise_price":0.2,"exercise_date":"2021-12-01","expiration_date":"2022-01-31","underlying":"Common Stock","underlying_shares":1297635},"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290504,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-04-27T01:25:54.000Z","date":"2021-12-30","kind":"exercise","acquired":true,"shares":1137635,"price":0.2,"value":227527.0,"ownership":{"direct":true},"balance_after":2127326,"source":{"system":"sec-edgar","filing":"0001437749-22-009783","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009783/rdgdoc.xml","form_type":"5"}},{"id":2290503,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":900000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F9","text":"Compensation warrants acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"}],"balance_after":900000,"derivative":{"exercise_price":0.4,"exercise_date":"2020-10-05","expiration_date":"2025-10-05","underlying":"Common Stock","underlying_shares":900000},"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290502,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"disposition_to_issuer","acquired":false,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F7","text":"Cancelled in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported transactions involved a recapitalization resulting in the deemed cancellation of the \"old\" warrants and the deemed grant of \"replacement\" warrants."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares"},{"field":"derivative.expiration_date","element":"expirationDate","label":"F8","text":"Originally exercisable on 11/15/19 and 12/06/19, with expirations of 11/15/24 and 12/06/24, respectively, for 15,000 shares and 30,000 shares"}],"balance_after":0,"derivative":{"exercise_price":0.4,"underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290501,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":397635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F5","text":"Acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The reported transactions involved a recapitalization resulting in the deemed cancellation of the \"old\" warrants and the deemed grant of \"replacement\" warrants."}],"balance_after":397635,"derivative":{"exercise_price":0.4,"exercise_date":"2020-10-05","expiration_date":"2025-10-05","underlying":"Common Stock","underlying_shares":397635},"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290500,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":50000,"price":0.4,"value":20000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F4","text":"Purchase shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"}],"balance_after":989691,"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290499,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":82545,"price":0.4,"value":33018.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F3","text":"Conversion shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"}],"balance_after":939691,"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290498,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Common Stock","published_at":"2022-04-27T01:22:58.000Z","date":"2020-10-05","kind":"grant","acquired":true,"shares":300000,"price":0.4,"value":120000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F2","text":"Compensation shares acquired in accordance with Recapitalization Agreement Schedule dated as of October 5, 2020"}],"balance_after":857146,"source":{"system":"sec-edgar","filing":"0001437749-22-009780","document":"rdgdoc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009780/rdgdoc.xml","form_type":"5"}},{"id":2290497,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:18:18.000Z","date":"2019-12-06","kind":"grant","acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired in connection with Note Purchase Agreement dated as of November 15, 2019"}],"balance_after":45000,"derivative":{"exercise_price":0.4,"exercise_date":"2019-12-06","expiration_date":"2024-12-06","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001437749-22-009776","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009776/rdgdoc.xml","form_type":"5"}},{"id":2290496,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"officer_title":"CEO/CFO"}}],"security":"Warrants to purchase Common Stock","published_at":"2022-04-27T01:18:18.000Z","date":"2019-11-15","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction approved by Board of Directors of Issuer and Non-Employee Directors"},{"field":"shares","element":"transactionShares","label":"F2","text":"Acquired in connection with Note Purchase Agreement dated as of November 15, 2019"}],"balance_after":15000,"derivative":{"exercise_price":0.4,"exercise_date":"2019-11-15","expiration_date":"2024-11-15","underlying":"Common Stock","underlying_shares":15000},"source":{"system":"sec-edgar","filing":"0001437749-22-009776","document":"rdgdoc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000143774922009776/rdgdoc.xml","form_type":"5"}},{"id":3710140,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CFO"}}],"security":"Option to Purchase Common Stock","published_at":"2019-01-03T17:04:46.000Z","date":"2019-01-01","kind":"grant","acquired":true,"shares":125000,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":125000,"derivative":{"exercise_price":0.4,"exercise_date":"2019-01-01","expiration_date":"2026-01-01","underlying":"COMMON STOCK","underlying_shares":125000},"source":{"system":"sec-edgar","filing":"0001091596-19-000005","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000109159619000005/primary_doc.xml","form_type":"4"}},{"id":3846477,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CFO"}}],"security":"Option to Purchase Common Stock","published_at":"2018-08-13T20:00:38.000Z","date":"2018-08-09","kind":"grant","acquired":true,"shares":192710,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":192710,"derivative":{"exercise_price":0.4,"exercise_date":"2018-08-09","expiration_date":"2025-08-09","underlying":"COMMON STOCK","underlying_shares":192710},"source":{"system":"sec-edgar","filing":"0001605411-18-000003","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000160541118000003/primary_doc.xml","form_type":"4"}},{"id":4235559,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"CEO, CFO"}}],"security":"COMMON STOCK","published_at":"2017-08-14T19:39:11.000Z","date":"2017-08-10","kind":"purchase","acquired":true,"shares":247500,"price":0.2222,"value":54994.5,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"Includes shares held jointly with spouse and shares held in IRA."}],"balance_after":557146,"source":{"system":"sec-edgar","filing":"0001674752-17-000002","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000167475217000002/primary_doc.xml","form_type":"4"}},{"id":4279108,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Warrant","published_at":"2017-06-16T14:14:06.000Z","date":"2017-06-14","kind":"purchase","acquired":true,"shares":32727,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Issued pursuant to a private placement in connection with the purchase of common stock in a registered direct offering."}],"balance_after":32727,"derivative":{"exercise_price":7.5,"exercise_date":"2017-12-15","expiration_date":"2027-06-14","underlying":"Common Stock","underlying_shares":32727},"source":{"system":"sec-edgar","filing":"0001313516-17-000001","document":"primary_doc.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000131351617000001/primary_doc.xml","form_type":"4"}},{"id":4279107,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":false,"officer":true,"ten_percent_owner":true,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-06-16T14:14:06.000Z","date":"2017-06-14","kind":"purchase","acquired":true,"shares":32727,"price":6.875,"value":224998.125,"ownership":{"direct":true},"balance_after":151913,"source":{"system":"sec-edgar","filing":"0001313516-17-000001","document":"primary_doc.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000131351617000001/primary_doc.xml","form_type":"4"}},{"id":4348638,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Options","published_at":"2017-04-20T21:16:35.000Z","date":"2017-04-19","kind":"grant","acquired":true,"shares":33753,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Received in connection with the Merger in exchange for an employee stock option to buy 42,857 shares of PLx Opco Inc. common stock for $9.80 per share."}],"balance_after":33753,"derivative":{"exercise_price":12.44,"exercise_date":"2017-04-19","expiration_date":"2025-07-22","underlying":"Common Stock","underlying_shares":33753},"source":{"system":"sec-edgar","filing":"0001144204-17-021382","document":"v464780_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000114420417021382/v464780_4.xml","form_type":"4"}},{"id":4348637,"issuer":{"id":129056,"kind":"organization","name":"PLx Pharma Inc.","symbol":"PLXP"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Acting Chief Financial Officer"}}],"security":"Common Stock","published_at":"2017-04-20T21:16:35.000Z","date":"2017-04-19","kind":"grant","acquired":true,"shares":119186,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received in exchange for 151,336 shares of common stock of PLx Opco Inc. (formerly PLx Pharma Inc.) in connection with the merger (the \"Merger\") of PLx Opco Inc. with a wholly owned subsidiary of PLx Pharma Inc. (formerly Dipexium Pharmaceuticals, Inc.)."}],"balance_after":119186,"source":{"system":"sec-edgar","filing":"0001144204-17-021382","document":"v464780_4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1497504/000114420417021382/v464780_4.xml","form_type":"4"}},{"id":4493255,"issuer":{"id":7149,"kind":"organization","name":"Nuo Therapeutics, Inc.","symbol":"AURX"},"owners":[{"id":18479,"kind":"person","name":"JORDEN DAVID EMERSON","position":1,"cik":"0001313516","reported_name":"JORDEN DAVID EMERSON","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"CEO, CFO"}}],"security":"Option to purchase Common Stock","published_at":"2017-01-12T01:19:23.000Z","date":"2017-01-09","kind":"grant","acquired":true,"shares":162500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"date","element":"transactionDate","label":"F1","text":"The grant of these options was approved by the issuer's board of directors on July 1, 2016, subject to stockholder approval of the 2016 Omnibus Incentive Compensation Plan under which the options were granted. Stockholder approval was obtained by means of a written consent and the issuer filed a related Information Statement on Schedule 14C with the SEC on November 25, 2016. The stockholder approval became effective on January 9, 2017. The option grant disclosed herein does not include options to purchase 187,500 shares subject to performance conditions, which have not yet vested and are therefore not yet reportable on Form 4."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Of these options, 62,500 vested immediately, and 50,000 each will vest on 3/31/17 and 12/31/17."}],"balance_after":162500,"derivative":{"exercise_price":1,"expiration_date":"2026-07-01","underlying":"Common Stock","underlying_shares":162500},"source":{"system":"sec-edgar","filing":"0001144204-17-001882","document":"v456665_4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1091596/000114420417001882/v456665_4.xml","form_type":"4"}}]}